Increased activity of
transcription factor NF-κB has been implicated in many
B-cell lymphomas. We investigated effects of synthetic compound
calafianin monomer (
CM101) on biochemical and
biological properties of NF-κB. In human 293 cells,
CM101 selectively inhibited
DNA binding by overexpressed NF-κB subunits REL (human c-Rel) and p65 as compared to NF-κB p50, and inhibition of REL and p65
DNA binding by
CM101 required a conserved
cysteine residue.
CM101 also inhibited
DNA binding by REL in human B-
lymphoma cell lines, and the sensitivity of several B-
lymphoma cell lines to CM101-induced proliferation arrest and apoptosis correlated with levels of cellular and nuclear REL.
CM101 treatment induced both phosphorylation and decreased expression of
anti-apoptotic protein Bcl-XL, a REL target gene product, in sensitive B-
lymphoma cell lines. Ectopic expression of Bcl-XL protected SUDHL-2 B-
lymphoma cells against CM101-induced apoptosis, and overexpression of a transforming mutant of REL decreased the sensitivity of BJAB B-
lymphoma cells to CM101-induced apoptosis.
Lipopolysaccharide-induced activation of NF-κB signaling upstream components occurred in RAW264.7 macrophages at
CM101 concentrations that blocked NF-κB
DNA binding. Direct inhibitors of REL may be useful for treating
B-cell lymphomas in which REL is active, and may inhibit B-
lymphoma cell growth at doses that do not affect some immune-related responses in normal cells.